Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that it has entered into a Master Service and Joint Venture Agreement (the “JV”) with TheraCell Advanced Biotechnology (“TheraCell”), for the clinical development and commercialization of cell and gene therapies. The JV will implement Orgenesis’ point-of-care (“POCare”) cell therapy strategy with a goal to bring Advanced Therapy Medicinal Products (ATMPs) to patients at the therapeutic setting by leveraging Orgenesis’ and TheraCell’s combined technical, regulatory and commercial expertise in Greece, Cyprus, Balkan region and Turkey.
Under the Master Service Agreement, Orgenesis will provide regulatory consultancy services, pre-clinical studies, intellectual property (IP) services including IP life cycle management, and POCare services including training and technical runs, quality management systems and operational support.
TheraCell is a regenerative biotechnology company with operations in Greece, where its laboratories and primary facilities are located. The Company focuses in the areas of autologous cell therapy and regenerative medicine. TheraCell has extensive experience in the isolation, processing and application of adipose derived stem cells (ADSCs), as well as somatic cells and has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, chondral defects and chronic kidney injury.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.